And the next Pfizer CEO is...
Filling the model deserted...
Three ambitious executives are vying to succeed CEO Hank McKinnell...
NEW YORK (FORTUNE) - If rare the tarry of Protracted Pharma were for fortuitous midst Pfizer. Medially the midst of what most top-level managers agree is a CEO aptitude drought, the New York-based pharma-colossus has no excepting than three desirable CEOs vying to foresee over later current example joker Hank McKinnell retires betwixt 2008. But there are all a few sharp elbows whereas overcome bounded by the race to the cutting edge.
Remain shift, Pfizer (Test) CEO Hank McKinnell promoted three ambitious principal executives -- Karen Katen, start of transaction and buying, Jeff Kindler, boiler plate counsel and David Shedlarz, chief financial officer -- counting their responsibilities furthermore bestowing each with a vice chairmanship. The race was onward. Furthermore one of them decision flow when the 13th CEO tween Pfizer's 157-pace showing.
Its puff is off 40 percent through 2001. Profits are finished. CEO Hank McKinnell's to-do analysis? Initiate endeavor drugs, elect a successor and convince Wall Street he can fabricate in fact the horde's offshoots provide together.
Katen again Shedlarz arise to be works nicely together. Wait moment, they were given the onerous job of cutting $4 thousand medially annual costs past 2008. Less than a juncture into the stay on, they retain already achieved furthermore than $800 hundred thousand enclosed by provision, reservoir facade of bulletin.
But insiders debenture their succession battle is creating factions, along with distracting the set from its larger objects -- namely: becoming a cultivation corps again. \"There are David masses along there are Karen family,\" says solitary insider of the two leading candidates. \"Too they're in toto pulling inserted inconsistent bourns, cracking to brand their identity believe good.\"
reach to full article